A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 12 Jun 2017 Planned End Date changed from 1 Oct 2017 to 15 Jun 2018.
- 12 Jun 2017 Planned primary completion date changed from 1 Oct 2017 to 12 Feb 2018.
- 27 Jun 2016 Status changed from not yet recruiting to recruiting.